Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHARP: Oncochip for Metastatic Breast Cancer
NCT06727357Phase 2Active, not recruiting
- Sponsor
- European Institute of Oncology
- Start
- Sep 2019
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vistusertib, selumetinib, olaparib and bicalutamide in breast cancer (5 arms), sponsored by European Institute of Oncology. Primary endpoint: Progression-Free Survival at 12 months. Started Sep 2019; status: active, not recruiting.
02
Drugs
vistusertibselumetinibolaparibbicalutamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06727357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727357.